Industry

First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that a supplemental New Drug Application (sNDA) for LYNPARZA in … [Read more…]

First PARP inhibitor to demonstrate clinical benefit in combination with a new hormonal agent irrespective of homologous recombination repair (HRR) gene mutations WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca’s supplemental New Drug Application (sNDA) for LYNPARZA® (olaparib) in combination with abiraterone and prednisone or prednisolone has been accepted and granted Priority Review in the US for the treatment of … [Read more…]

Restore Moves Up From No. 426 in 2021 to No. 411 in 2022 on the Inc. 5000 Ranking of America’s Fastest-Growing Private Companies AUSTIN, Texas–(BUSINESS WIRE)–Today, Inc. revealed that Restore Hyper Wellness (Restore), the leading provider of proactive wellness services, ranked No. 411 on its annual Inc. 5000 list, the most prestigious ranking of the … [Read more…]

PORTOLA VALLEY, Calif.–(BUSINESS WIRE)–TransMed7, LLC announced today that the “First in Human” clinical case of the commercial production version of a Heron™ XPS device (a member of the new Heron™ family of vacuum-assisted, Single Insertion / Multiple Collection (SIMC®) Soft Tissue Biopsy devices) was successfully performed by Dr. Edgar Staren, a surgical oncologist with the … [Read more…]

AUSTIN, Texas & LONDON–(BUSINESS WIRE)–Babylon Holdings Limited (NYSE: BBLN) (“Babylon” or the “Company”), one of the world’s fastest-growing digital healthcare companies, released a statement yesterday addressing the M&A speculation and a more than 20% increase in the Company’s stock price at one point during the trading day that led to the New York Stock Exchange’s … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “High Potency APIs Global Market Opportunities And Strategies To 2031” report has been added to ResearchAndMarkets.com’s offering. The global high potency APIs market reached a value of nearly $19,772.2 million in 2021, having grown at a compound annual growth rate (CAGR) of 5.2% since 2016. The market is expected to grow from $19,772.2 … [Read more…]

IRVINE, Calif.–(BUSINESS WIRE)–Today Viseon Inc. announced that it has received Quality Management and CE Mark Certification for their MaxView® System device under the new MDR. The EU MDR is the set of regulations that governs the worldwide production and European distribution of medical devices. Compliance with this regulation is mandatory for medical device companies to … [Read more…]

SleepScore ranks 417th out of 5,000 companies, 65th in California CARLSBAD, Calif.–(BUSINESS WIRE)–SleepScore Labs, the company behind the science of sleep improvement, today announced it has made the prestigious Inc. 5000 Fastest Growing Companies in America list for the first time. SleepScore ranked 417th out of 5,000 companies, and was recognized as 65th in California, … [Read more…]

Researchers are invited to apply to receive DNA that has been synthesised using Evonetix’s platform CAMBRIDGE, England–(BUSINESS WIRE)–EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the opening of its early access program for semiconductor synthesised DNA. Evonetix’s DNA synthesis capability brings together patented semiconductor chip design and proprietary, … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Painful Diabetic Neuropathy Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030” report has been added to ResearchAndMarkets.com’s offering. The Painful Diabetic Neuropathy Drugs Market is forecasted to grow at a CAGR of 7% during the forecast period of 2022 to 2030. … [Read more…]